Mantle-cell lymphoma: classification and therapeutic implications.
Mantle-cell lymphomas have been recognized in the new Revised European-American Lymphoma Classification as a peripheral B-cell neoplasm that has a distinct morphologic, immunologic, and genetic phenotype. Mantle-cell lymphomas have been subtyped into four categories, termed 'mantle zone', 'nodular', 'diffuse', or 'blastoid'. The incidence of the 'mantle-zone' pattern remains controversial. The fact that patients with the nodular, diffuse, or blastoid subtypes of mantle-cell lymphoma have a high proliferative rate resulting from overexpression of the cyclin D1 and a very short median survival demonstrates conclusively that these patients should be categorized as having an aggressive lymphoma. Most authorities believe that the 'mantle zone' variant pursues a more benign clinical course than the other subtypes. Trials of the new purine analogs are of great interest in these mantle-zone lymphoma patients.
Fisher
R I
RI
Division of Hematology/Oncology, Loyola University Cancer Center, Maywood, IL, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000145:classification* / Q000188:drug therapy* / Q000473:pathology; D011687:Purines / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D011687:Purines